Diabetes drug shown to improve A1c levels in trial

SAN DIEGO Patients treated with an investigational drug for Type 2 diabetes showed improved A1c levels in the blood, according to results of a mid-stage trial released Monday.

Harbor BioSciences said it found no significant difference in A1c levels between patients taking Triolex and those taking placebo in a phase 2a trial of the drug overall, but that the drug decreased obesity-induced inflammation and insulin resistance in patients with the disease.


“Chronic tissue inflammation is emerging as a substantial cause of insulin resistance in obese patients with Type 2 diabetes, so it is important to fully explore the potential of anti-inflammatory therapeutic approaches to this disease,” University of California San Diego medicine professor and dean for scientific affairs Jerrold Olefsky said in a statement. “Triolex produced excellent anti-inflammatory, insulin-sensitizing effects in preclinical studies. The early clinical results in the more obese patients with elevated signs of inflammation show some promise and should be further explored.”

Login or Register to post a comment.